ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia
- Resource Type
- Article
- Source
- In
European Neuropsychopharmacology October 2014 24(10):1698-1708 - Subject
- Language
- ISSN
- 0924-977X